Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Pharmacometric and statistical considerations for dose optimization.

Chotsiri P. et al, (2024), CPT Pharmacometrics Syst Pharmacol

In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever.

Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol

Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections.

Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling WHK. et al, (2024), PLoS Med, 21

Determination of ivermectin in plasma and whole blood using LC-MS/MS

Kaewkhao N. et al, (2024), Wellcome Open Research, 9, 231 - 231

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

Watson JA. et al, (2024)

Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants

Banda CG. et al, (2024), British Journal of Clinical Pharmacology

A pharmacokinetic randomised interventional study to optimise dihydroartemisinin-piperaquine dosing for malaria preventive treatment in Malawian infants: A protocol for the OPTIMAL study

Banda CG. et al, (2024), Wellcome Open Research, 9, 291 - 291

Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine, and chloroquine in Rhesus macaques.

Vanachayangkul P. et al, (2024), Antimicrob Agents Chemother

Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants.

Wattanakul T. et al, (2024), Nat Commun, 15

Comparison of lumefantrine, mefloquine, and piperaquine concentrations between capillary plasma and venous plasma samples in pregnant women with uncomplicated falciparum and vivax malaria.

Saito M. et al, (2024), Antimicrob Agents Chemother, 68

Determination of ivermectin in plasma and whole blood using LC-MS/MS

Kaewkhao N. et al, (2024), Wellcome Open Research, 9, 231 - 231

Medication adherence framework: A population-based pharmacokinetic approach and its application in antimalarial treatment assessments.

Ding J. et al, (2024), CPT Pharmacometrics Syst Pharmacol

Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

Chan XHS. et al, (2024)

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'.

Watson JA. et al, (2024), Elife, 13

A high-throughput LC-MS/MS assay for piperaquine from dried blood spots: Improving malaria treatment in resource-limited settings.

Blessborn D. et al, (2024), J Mass Spectrom Adv Clin Lab, 31, 19 - 26

Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimisation in infants

Banda C. et al, (2023)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance.

Cavany S. et al, (2023), Nat Commun, 14

Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria.

Mukaka M. et al, (2023), EBioMedicine, 96

Evidence based optimal dosing of intravenous artesunate in children with severe falciparum malaria.

Haghiri A. et al, (2023), Clin Pharmacol Ther

Load More

Include forthcoming?